 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Effect of Troglitazone on Pre-Clinical Carotid Atherosclerosis in Women with Recent Gestational Diabetes"Prof. Thomas A. Buchanan (biography)
English - 2005-06-10 - 26 minutes
|
 | (18 slides) |
Summary :
In this presentation Prof. Buchanan discusses data from the TRIPOD (Troglitazone in the Prevention of Diabetes) study on the impact of troglitazone treatment on the progression of pre-clinical atherosclerosis in high-risk Hispanic women with recent gestational diabetes, and mechanisms by which troglitazone may slow this progression.
Carotid intima media thickness (IMT) serves as a measure of pre-clinical atherosclerosis. The rate of change of IMT over time is predictive of cardiovascular events, and IMT has been found to correlate with insulin resistance in cross-sectional studies. Women in the TRIPOD study were insulin resistant and at high risk for type 2 diabetes, and therefore atherosclerosis, so one question asked was whether troglitazone would have any effect on IMT progression in these women.
In the carotid IMT analysis of the study, 192 subjects were randomized to placebo or a 400mg daily dose of the insulin-sensitizing thiazolidinedione drug troglitazone, with a follow-up of roughly 1 to 5 years. In the overall unadjusted analysis troglitazone was associated with a 31% reduction in the rate of IMT progression. Prof. Buchanan discusses the effect in relation to changes in glucose, insulin, lipid levels and insulin sensitivity during treatment, and possible direct and indirect mechanisms whereby troglitazone could have this effect on IMT progression.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- Data from the IMT analysis of the TRIPOD Study, showing the effect of troglitazone on IMT progression in Hispanic women at high risk for type 2 diabetes.
Bibliographic references :
Anny H. Xiang, Ruth K. Peters, Siri L. Kjos, Cesar Ochoa, Aura Marroquin, Jose Goico, Sylvia Tan, Chengwei Wang, Stanley P. Azen, Chao-ran Liu, Ci-hua Liu, Howard N. Hodis and Thomas A. Buchanan. Effect of Thiazolidinedione Treatment on Progression of Subclinical Atherosclerosis in Premenopausal Women at High Risk for Type 2 Diabetes J Clin Endocrinol Metab. 2005 Apr;90(4):1986-91.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
